Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
GSK is doubling down on oncology with a deal worth up to $750 million to license a trispecific T cell-engager (TCE) from China's Chimagen Biosciences. The drug is designed to supercharge T cells against tumors while minimizing off-target effects, and GSK plans to develop it for multiple myeloma. Phase 1 trials are expected to kick off in 2027.
GSK is continuing its oncology expansion with a deal worth up to $750 million to acquire global rights to a trispecific T cell-engager (TCE) from China-based Chimagen Biosciences. The engineered protein works by simultaneously bringing T cells and tumor cells together while blocking immune checkpoints — a triple-action approach designed to boost cancer-killing power with fewer off-target side effects. GSK plans to develop the drug specifically for multiple myeloma, a blood cancer, with Phase 1 trials slated to begin in 2027.
The deal is the latest move in an aggressive oncology push under new CEO Luke Miels, who is racing to build out GSK's cancer portfolio ahead of looming patent expirations on its blockbuster HIV drugs. This isn't GSK's first rodeo with Chimagen either — in 2024, the two companies struck an up-to-$850 million deal for a separate experimental drug.
By the Numbers:
Why it matters: As patent cliffs loom over GSK's HIV franchise, the company is aggressively repositioning itself as an oncology powerhouse. This TCE deal signals growing industry interest in next-generation, multi-target immune therapies for hard-to-treat blood cancers like multiple myeloma.
